The Latest Cardiac and Vascular News
LONDON–(BUSINESS WIRE)–BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel target for Heart Failure to its discovery portfolio through its collaboration with BenevolentAI. Novel target for Heart Failure was discovered using BenevolentAI’s AI-drug […]
CARLSBAD, Calif., July 28, 2023 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced it has expanded its existing collaboration with AstraZeneca to include exclusive rights for AstraZeneca to commercialize eplontersen in Latin America. Ionis previously granted AstraZeneca exclusive rights to commercialize eplontersen in all other countries outside the U.S. Ionis and AstraZeneca will continue to jointly […]
FDA approval means patients with heart failure can benefit from FARXIGA regardless of left ventricular ejection fraction status WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca’s FARXIGA (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalization for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. The […]
LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that AstraZeneca has nominated the first product candidate under its siRNA (short interfering RNA) collaboration and will pay Silence a […]
WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca is commencing today, through a subsidiary, a tender offer to purchase all outstanding shares of CinCor Pharma, Inc. (CinCor), for $26 per share in cash at closing, plus a non-tradable contingent value right of $10 per share in cash payable upon a specified regulatory submission for a […]
WALTHAM, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (NASDAQ: CINC) today announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has agreed to acquire CinCor. Marc de Garidel, Chief Executive Officer at CinCor, said: “We are excited about the proposed acquisition of […]
Collaboration will advance the development of compounds designed by Gatehouse Bio’s AI-Powered platform September 08, 2022 08:16 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–Gatehouse Bio, a pioneer in small RNA therapeutics, and AstraZeneca, a global, science-led biopharmaceutical company, are advancing their partnership, to create RNA therapeutics for the treatment of heart failure […]
Results presented at European Society of Cardiology Congress 2022, and published in New England Journal of Medicine Data extend the clinically meaningful benefits of FARXIGA in patients with heart failure regardless of ejection fraction Heart failure is a chronic, progressive disease impacting nearly 64 million people August 27, 2022 10:36 AM Eastern […]
Two novel targets identified through the existing collaboration have already been added to AstraZeneca’s portfolio LONDON, Jan. 13, 2022 /PRNewswire/ — BenevolentAI, a leading clinical-stage AI drug discovery company, has expanded its AI-driven drug discovery collaboration with AstraZeneca, doubling the number of disease areas being explored through the partnership. The three-year expansion includes an […]
WILMINGTON, Del.–(BUSINESS WIRE)–Today on World Heart Day, the AstraZeneca HealthCare Foundation has awarded seven innovative, community-based nonprofit organizations $954,311 in grants across seven US states to address cardiovascular disease, a leading cause of death in the nation. The grants are part of the Foundation’s signature Connections for Cardiovascular HealthSM (CCH) Next Generation program, now in […]
